ReviewMagyar onkologia2025
[Immunotherapy for urological cancers in 2025].
Review in Magyar onkologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo review the development of immunotherapy (IO) for urological cancers (urothelial carcinoma - UC, renal cell carcinoma - RCC, prostate cancer - PCa , testicular germ cell tumors - TGCT) with a focus on the latest studies, combination strategies, and the messages of the 2025 guidelines.
methodsReview of randomized phase II-III studies published in 2024-2025, international guidelines, and biomarker- guided approaches.
resultsIn UC, the combination of enfortumab vedotin and pembrolizumab has been a breakthrough and has become the new first-line standard, while maintenance and adjuvant immunotherapies have also been strengthened. In RCC, IO- TKI and IO-IO combinations show long-term survival benefits, but the IO-after-IO strategy has proven questionable. In PCa, the efficacy of immunotherapy is mainly limited to biomarker-driven subgroups (MSI-H/dMMR), while in TGCT, cisplatin-based treatment remains the standard, and the role of IOs is being evaluated in further studies.
conclusionsBy 2025, immunotherapy has become the therapeutic basis for UC and RCC, both in metastatic and curative treatments. In PCa and TGCT, immunotherapy options remain in the experimental phase, but research is ongoing with new combinations and biomarker-driven strategies.
Indexed as
Identifiers
41385769PMC12701788What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.